John Farnam of Receptos has been named as COO of Kura Oncology. He will start in the newly created position July 1.

Kura’s lead drug candidate is Tipifarnib, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications.

Farnam since 2015 has been vice president of business operations at Receptos, which New Jersey-based Celgene acquired for $7.2 billion.

Before that, Farnam served for 26 years as an officer in the Marine Corps, serving as an FA-18D squadron commanding officer and as the commanding officer of Marine Corps Air Station Miramar. He retired from the Marine Corps as a Colonel in 2015.

In addition, it was announced Bridget Martell and Blake Tomkinson joined the company as vice presidents of clinical development.